Home Linking preeclampsia and cardiovascular disease later in life
Article
Licensed
Unlicensed Requires Authentication

Linking preeclampsia and cardiovascular disease later in life

  • Yves Giguère EMAIL logo , Marc Charland , Sébastien Thériault , Emmanuel Bujold , Mélissa Laroche , François Rousseau , Julie Lafond and Jean-Claude Forest
Published/Copyright: November 23, 2011

Abstract

Preeclampsia (PE), which is defined as new onset hypertension after 20 weeks of pregnancy accompanied by proteinuria, is characterized by inadequate placentation, oxidative stress, inflammation and widespread endothelial dysfunction. A link between PE and long-term risk of cardiovascular disease (CVD) was suggested by retrospective studies, which found that PE was associated with a 2–3-fold risk of CVD later in life, with a 5–7-fold risk in the case of severe and/or early-onset PE. Recently, meta-analyses and prospective studies have confirmed the association between PE and the emergence of an unfavorable CVD risk profile, in particular a 3–5-fold increased prevalence of the metabolic syndrome only 8 years after the index pregnancy. PE and CVD share many risk factors, including obesity, hypertension, dyslipidemia, hypercoagulability, insulin resistance and both entities are characterized by endothelial dysfunction. PE and CVD are complex traits sharing common risk factors and pathophysiological processes, but the genetic link between both remains to be elucidated. However, recent evidence suggests that genetic determinants associated with the metabolic syndrome, inflammation and subsequent endothelial dysfunction are involved. As the evidence now supports that PE represents a risk factor for the emergence of the metabolic syndrome and CVD later in life, the importance of long-term follow-up assessment of CVD risk beginning early in women with a history of PE must be considered and translated into new preventive measures.


Corresponding author: Yves Giguère, CRCHUQ, Hôpital Saint-François d’Assise, 10, rue de l’Espinay, Québec City, QC, G1L 3L5, Canada Phone: +1-418-525-4444 ext. 53712, Fax: +1-418-525-4195

Received: 2011-6-30
Accepted: 2011-9-5
Published Online: 2011-11-23
Published in Print: 2012-06-01

©2012 by Walter de Gruyter Berlin Boston

Articles in the same Issue

  1. Masthead
  2. Masthead
  3. Editorial
  4. Laboratory maternal-fetal medicine: challenges and perspectives
  5. Reviews
  6. Candidate biochemical markers for screening of pre-eclampsia in early pregnancy
  7. Linking preeclampsia and cardiovascular disease later in life
  8. Mini Reviews
  9. Fetal nucleic acids in maternal blood: the promises
  10. Ethical aspects of the expansion of neonatal screening programme due to technological advances
  11. Prenatal screening for trisomy 21: recent advances and guidelines
  12. Ultrasound markers for the detection of women at risk of developing pre-eclampsia
  13. Are biological markers relevant for the diagnosis and the prognosis of preterm premature rupture of membranes (PPROM)?
  14. Genetics and Molecular Diagnostics
  15. Study of FTMT and ABCA4 genes in a patient affected by age-related macular degeneration: identification and analysis of new mutations
  16. Rapid detection of CFH (p.Y402H) and ARMS2 (p.A69S) polymorphisms in age-related macular degeneration using high-resolution melting analysis
  17. Unlabeled-probe high-resolution melting to detect KRAS codon 12 and 13 mutations in pancreatic adenocarcinoma tissues
  18. General Clinical Chemistry and Laboratory Medicine
  19. Volume, rates, source and types of add-on pathology test requests across five hospitals
  20. Schizophrenia is associated with increased levels of serum Fas and FasL
  21. Comparison between capillary, venous and arterial levels of protein S100B in patients with severe brain pathology
  22. Changes of serum adiponectin and soluble intercellular adhesion molecule-1 concentrations after smoking cessation
  23. Lack of consistency between two commercial ELISAs and against an in-house ELISA for the detection of CD36 in human plasma
  24. Comparison of a commercial urinary neopterin radioimmunoassay with high performance liquid chromatography
  25. Evaluation of Prevent ID and Quantum Blue rapid tests for fecal calprotectin
  26. Analytical performance evaluation of four cartridge-type blood gas analyzers
  27. Cancer Diagnostics
  28. Serum free light chains and oligoclonal bands in patients with multiple myeloma and autologous stem cell transplantation
  29. Cardiovascular Diseases
  30. Homocysteine as a determinant of left ventricular ejection fraction in patients with diabetes
  31. Plasma total homocysteine is a determinant of carotid intima-media thickness and circulating endothelial progenitor cells in patients with newly diagnosed hypertension
  32. Serum MMP-9 and TIMP-1 concentrations and MMP-9 activity during surgery-induced inflammation in humans
  33. Effects of endothelin-1 on endothelial progenitor cell function
  34. Investigation of cystatin C and cystatin C based estimated glomerular filtration rate in pregnant patients with heart failure
  35. Letters to the Editor
  36. Comments on a performance evaluation of cartridge-type blood gas analyzers
  37. Comments on a performance evaluation of cartridge-type blood gas analyzers. Reply
  38. Carryover can be a cause of false-positive results with the Beckman AccuTnI assay
  39. Method comparison of a 25-hydroxy vitamin D enzyme immunoassay to liquid chromatography tandem mass spectroscopy
  40. Bone marrow plasma cell separation – validation of separation algorithm
  41. Sharing our experience in improving postgraduate clinical biochemistry training with laboratory practice articles
Downloaded on 17.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm.2011.764/html
Scroll to top button